Navigation Links
Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference

NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that data from a follow-up to a Phase 3 multi- national clinical trial shows the combination of DOXIL(R) with VELCADE(R) improves the probability of survival by 41%. The follow-up study also showed no increase in serious side effects such as neuropathy with the addition of DOXIL to the VELCADE. The findings were presented at the American Society of Clinical Oncology (ASCO) global cancer meeting in Chicago.

The VELCADE/DOXIL combination was approved by the FDA just last month as a new treatment option for myeloma patients who have relapsed or who have not responded to at least one other course of treatment. The drugs work in combination because there is evidence that VELCADE increases the effectiveness of DOXIL against cancer cells and DOXIL does the same for VELCADE.

"'Improved survival' are words that every cancer patient wants to hear, and we are encouraged to have this new option to offer patients with peer reviewed data behind it," said Susie Novis, president and co-founder of the IMF. "Until there is a cure, we are moving myeloma toward becoming a chronic disease with long term survival achieved by using drugs in combination and in sequence. The VELCADE/DOXIL combination fits perfectly into this paradigm and offers an important and powerful new opportunity to extend and improve patients' lives."

DOXIL is a specially (liposomal) formulated version of the chemotherapy agent doxorubicin, and is approved for use in other forms of cancer. VELCADE, bortezomib, is approved for myeloma patients who have relapsed or not responded to a previous course of treatment. The findings come from a 14 month follow-up to a multi-national trial involving nearly 650 patients.

Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects production of red cells, white cells and stem cells. It affects an estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing numbers and in increasingly younger people.

ABOUT The International Myeloma Foundation

The International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 135,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses on four key areas: research, education, support and advocacy. To date, the IMF has conducted more than 100 educational seminars worldwide, maintains a world-renowned hotline, and operates Bank on a Cure(R), a unique gene bank to advance myeloma research. The IMF can be reached at 818-487-7455. The global Website is www.myeloma.org with a companion Website in Spanish at www.myelomala.org.

    CONTACT:

    International Myeloma Foundation

    800 452-2873

    Media:

    Peggy Frank

    818 735-3591

CONTACT: Peggy Frank, Media, +1-818-735-3591, for International MyelomaFoundation, +1-800-452-2873

Web site: http://www.myeloma.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):